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ABSTRACT
Background This paper explores the application of alternative approaches to economic evaluation of public health interventions, using a
worked example of exercise referral schemes (ERSs).
Methods Cost-utility (CUA) and cost-consequence analyses (CCA) were used to assess the cost-effectiveness of ERSs. For the CUA, evidence
was synthesized using a decision analytic model that adopts a lifetime horizon and NHS/Personal Social Services perspective. Outcomes were
expressed as incremental cost per quality-adjusted life-year (QALY). CCA was conducted from a partial-societal perspective, including health
and non-healthcare costs and benefits. Outcomes were reported in natural units, such as cases of strokes or CHD avoided.
Results Compared with usual care, the incremental cost per QALY of ERS is £20 876. Based on a cohort of 100 000 individuals, CCA
estimates cost of ERS at £22 million to the healthcare provider and £12 million to participants. The benefits of ERS include additional 3900
people becoming physically active, 51 cases of CHD avoided, 16 cases of stroke avoided, 86 cases of diabetes avoided and a gain of 800
QALYs.
Conclusions CCA might provide greater transparency than CUA in reporting the outcomes of public health interventions and have greater
resonance with stakeholders involved in commissioning these interventions.
Keywords cost-consequence analysis, cost-utility analysis, economic evaluation, physical activity, public health intervention
Background
Economic evaluation is increasingly used to inform deci-
sions on how healthcare resources are allocated. Much of
the effort to date has focused on the application of econom-
ics to innovative drugs and medical technologies, under
the auspices of health technology assessment. However,
there is increasing interest in exploring the cost-effectiveness
of a wider range of healthcare interventions, including
public health programmes.1 The rationale for this is
clear: public health interventions consume health (and other
public sector) resources and as such are associated with an
opportunity cost. That is, the money spent on public health
interventions could be allocated to other healthcare activities
and it is important to determine whether public health inter-
ventions offer comparable or superior health outcomes for
a similar level of expenditure.
Many of the prevailing methods of economic evaluation
in health care are based on a pharmaceutical paradigm,2
which assumes that there is high-quality evidence on their
effectiveness, typically derived from randomized controlled
trials (RCTs) conducted prior to widespread uptake in the
health service. Those familiar with public health interven-
tions will recognize that these methods may have severe lim-
itations when applied to interventions such as health
promotion. A number of economists have recognized the
shortcomings of the prevailing methods of economic evalu-
ation when applied to public health.2,3 Particular concerns
include the absence of robust evidence on effectiveness
from RCTs which typiﬁes many public health interventions;
the fact that costs and beneﬁts of public health interventions
may be accrued well beyond the health service and the rele-
vance of commonly used endpoints [quality-adjusted life-
year (QALY)] to public health stakeholders.
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The National Institute for Health and Clinical Excellence
(NICE) recognizes some of these limitations in the Methods
Manual that is intended to support the development of
public health guidance.1 Within this, NICE recommends
that public health interventions should be subject to eco-
nomic evaluation to determine their cost-effectiveness and
that the NICE Reference Case should be adopted wherever
possible, comprising cost-utility analysis (CUA) from a
healthcare perspective with outcomes reported in the form
of incremental costs per QALY. However, the guidance
acknowledges that the reference case has limitations in its
application to public health and also suggests alternative
methods that might be adopted. One favoured method is
cost-consequence analysis (CCA), which reports costs and
outcomes in a disaggregated fashion, unlike CUA that
adopts a composite outcome, the QALY. CCA might seem
particularly attractive for evaluating public health interven-
tions as it allows stakeholders from the health sector and
beyond to identify where costs and beneﬁts might be
accrued (e.g. health sector, local authority).1 CCA also offers
greater potential to consider the impact of programmes on
health inequalities by identifying particular sub-groups of
the population who may beneﬁt more. CUA typically pays
little attention to inequalities as it is founded on the prin-
ciple that a QALY is of equal value, regardless of the recipi-
ent.2,4 Whilst methods exist for equity weighting QALYs, in
practice these are rarely used due to insufﬁcient evidence on
the appropriate weights.5
This paper explores the issue of the appropriate method to
apply to economic evaluations of public health interventions,
using a worked example to compare the alternative ap-
proaches in an evaluation of exercise referral schemes
(ERSs). ERS is a common intervention used to encourage
physical activity in primary care.6 In an ERS, people who are
sedentary and/or have risk factor(s) for conditions known to
beneﬁt from physical activity are referred by a primary care
professional to a third party service (often a leisure centre),
which then prescribes and monitors an exercise programme
tailored to the individual needs of the patients.7
The objective is to present information on the cost-
effectiveness of ERS to promote physical activity using
CUA and CCA. The original research presented herein was
conducted as part of an assessment of the clinical and cost-
effectiveness of ERS to promote physical activity, funded by
the NIHR Health Technology Assessment Programme.
Methods
Table 1 describes the inputs to the model used for CUA.
This includes the estimates of the effectiveness of ERS on
physical activity levels, intervention costs associated with
ERS, probability of experiencing an outcome, utility values
and life years associated with each outcome.
Evidence on the effectiveness of ERS was identiﬁed from
a meta-analysis8 conducted alongside the economic evalu-
ation. This was based on ‘intention-to-treat’ analyses and
showed that people exposed to ERS were more likely [rela-
tive risk (RR): 1.11; 95% conﬁdence interval (CI): 0.99,
1.25] to become physically active compared with those
exposed to usual care. The usual care is no active interven-
tion, the recognized alternative in a sedentary population.
This acknowledges that sedentary individuals may participate
in physical activity without an intervention, although the
probability of doing so is assumed to increase after exposure
to ERS. In line with the effectiveness literature and physical
activity for health guidance,9 physically active state is deﬁned
as doing at least 90–150 min of at least moderate intensity
physical activity per week.
Evidence on the costs of ERS was identiﬁed from Isaacs
et al.,10 which included a detailed, bottom-up cost of ERS;
providing resource use in a health service/local authority
that comprises provision of facilities, exercise trainers and
administrative support for ERS. The validity of the resource
use and cost estimates were assessed by an expert advisory
group (including clinicians, exercise scientists and health
economists) and judged to be representative of ERS in
current practice. Cost estimates are inﬂated to 2010 prices,
using the consumer price index, for this current analysis.
Outcomes associated with physical activity (Table 1) were
derived from a previous analysis developed to inform NICE
guidance on physical activity.6 For the current analysis, the
conditions that are associated with physical activity included
coronary heart disease (CHD), stroke and type II diabetes.
Although many other conditions are thought to be asso-
ciated with physical activity, these three conditions were
selected because robust quantiﬁable evidence exists on their
relationship with physical activity.11 Evidence of the effect
of physical activity on these conditions is derived from sys-
tematic searches8 and the Health Survey for England (HSE)
2006 (survey year focused on cardiovascular disease and risk
factors). HSE is the main data source on morbidities in
England.12 The probability of developing CHD, stroke or
diabetes among sedentary individuals is generated from the
prevalence of these conditions in that population, using the
HSE 2006 data. The probability of developing these condi-
tions among active individuals are derived using RR esti-
mates to adjust the probabilities for the sedentary
individuals.6,13,14 The physical activity levels and population
used to measure the RR estimates match those of the
cohort considered here. In line with the literature on ERS,6
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a number of assumptions were made in generating these
estimates. First, the risk estimates were assumed to be
equivalent to the risk of developing those conditions over
life-time. Second, the risk of experiencing any of these con-
ditions was assumed to be independent of the risk of experi-
encing other conditions. Third, individuals were assumed to
experience only one condition within the model. Whilst a
potential limitation of this approach is that it inadequately
accounts for confounders, data constraints precluded their
inclusion.
For the CUA, evidence was synthesized using a decision
analytic model (Fig. 1) that adopts a lifetime horizon and
NHS/Personal Social Services perspective. The model con-
sidered a cohort of sedentary adults (40–60 years) who are
exposed to an ERS that is structured as leisure centre-based
intervention. This age group reﬂects the evidence on the ef-
fectiveness of ERS.8 Individuals enter the model as either
exposed to ERS or usual care. A physically active individual
is assumed to have both improved life expectancy and quality
of life, due to reduced risk of developing each of the morbid-
ities considered in the model. The probability of becoming
physically active is adjusted to reﬂect the effectiveness of
ERS.8 The lifetime risk of developing ill-health is adjusted
based on an individual’s level of physical activity. The primary
endpoint for the analysis was QALYs. Future costs and bene-
ﬁts are discounted at a rate of 3.5% per annum.15
Deterministic sensitivity analysis (one-way, scenario and
extreme values analysis) were used to address uncertainty
Table 1 Estimates of the inputs to the model used for the CUA
Input Value Data source
Effectiveness
Probability of becoming active after exposure to ERS 0.345 Pavey et al.8
Probability of becoming active after exposure to usual care 0.297 Pavey et al.8
Intervention costs
Cost of the intervention per participant to the providers £222 Pavey et al.8
Probability of experiencing an outcome associated with physical activity
Probability of experiencing CHD when active 0.014 HSE12; Shaper13
Probability of experiencing CHD when sedentary 0.027 HSE12; Shaper13
Probability of experiencing stroke when active 0.011 HSE12; Herman et al.14
Probability of experiencing stroke when sedentary 0.015 HSE12; Herman et al.14
Probability of experiencing type II diabetes when active 0.022 HSE12; NICE6
Probability of experiencing type II diabetes when sedentary 0.044 HSE12; NICE6
Inputs used in calculating QALYs/treatment costs
Utility/health state value of being in CHD state 0.55 Kind et al.18; NICE6
Utility/health state value of being in stroke state 0.52 Kind et al.18; NICE6
Utility/health state value of being in type II diabetes state 0.7 Kind et al.18; NICE6
Utility/health state value of being in a non-disease health state 0.83 Kind et al.18; NICE6
Average age of cohort (in years) 50 HSE12
Average age of mortality (in years) 84 ONS19
Assumed average age of onset of a disease health state (in years) 55 NICE6
Life years remaining after onset of CHD 18.41 NICE6; ONS19
Life years remaining after onset of stroke 5.12 NICE6; ONS19
Life years remaining after onset of type II diabetes 28.13 NICE6; ONS19
Lifetime treatment costs*/QALYs associated with health states (per person)
Lifetime treatment costs associated with CHD state £17 728 NICE6
Lifetime treatment costs associated with stroke state £1965 DH20
Lifetime treatment costs associated with type II diabetes state £50 309 Currie et al.21
Lifetime treatment costs associated with non-disease health state — —
QALYs associated with CHD state 9.94 Kind et al.18; NICE6
QALYs associated with stroke state 5.15 Kind et al.18; NICE6
QALYs associated with type II diabetes state 14.18 Kind et al.18; NICE6
QALYs associated with non-disease health state 17.18 Kind et al.18; NICE6
*Costs are in 2010 prices.
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around parameters considered to be key drivers of the cost-
effectiveness of ERS. These included uncertainties around
the effectiveness of ERS and changes in the cost of ERS to
account for costs incurred by participants and providers.10
The effectiveness of ERS varied according to estimates of
uncertainty reﬂected in upper and lower limits of 95% CI of
the RR estimate from the meta-analysis.8 Sensitivity analysis
also considered how a less intensive ERS might look, using
evidence on a walking-based intervention (as opposed to a
leisure centre-based intervention) from Isaacs et al.10 Further
sensitivity analyses considered ‘best-case’ and ‘worst-case’
scenarios which considered the combined effect of extreme
values of effectiveness and cost.
For the CCA, outcomes were reported in natural units,
such as the cases of CHD avoided. Further literature searches
were conducted to identify outcomes that are associated with
physical activity but where the magnitude of beneﬁt is poorly
deﬁned8; the CCA indicates the expected direction of change
but does not seek to quantify the beneﬁts. Costs were
reported in monetary units (2010 prices) and consideration
was given to whether costs were incurred by the health
service or the individual participating in ERS. The analysis
was conducted from a partial-societal perspective, including
health and non-healthcare costs and beneﬁts. The interven-
tion and its cost remain unchanged from the CUA.
Results
Cost-utility analysis
The estimated incremental cost-effectiveness ratio (ICER)
suggests that the incremental lifetime cost of ERS is
£170. Total costs and outcomes are presented in per
person terms. This additional investment generates 0.008
QALYs over the lifetime of an individual. The cost per
QALY of ERS is £20 876 and can be considered cost-
effective at £30 000.1 Adopting this threshold results in ERS
generating a net beneﬁt, i.e. the value of the health gains
measured in monetary terms exceeds the cost of ERS.
Table 2 shows the ﬁndings of the sensitivity analyses, in-
dicating the impact of the variation in parameter estimates
on the cost-effectiveness of ERS. Assuming a less-intensive
ERS or more-effective ERS resulted in an ICER lower
than the base case and ,£30 000 per QALY. Conversely,
including participants costs led to an ICER .£30 000
per QALY, whilst a less-effective ERS resulted in ERS
being dominated by usual care (negative ICER)—that is
ERS is more expensive and leads to QALY losses. The
scenario analysis suggests that in the worst-case scenario,
ERS was dominated by usual care. In the best-case scen-
ario, the ICER was ,£700 per QALY. Overall, the ICER
was most sensitive to changes in the scenarios (best cases
of cost and effectiveness).
Cost-consequence analysis
Table 3 summarizes the outcomes of the CCA. In an
attempt to present meaningful, population-level outcomes,
the analysis considers a cohort of 100 000 individuals who
might be eligible for ERS. The cost of ERS for this cohort
is estimated to be £22 million to the health care provider
and £12 million to the participants and total cost of £33
million. This is based on a leisure centre-based intervention
as deﬁned in the CUA.
The beneﬁts of ERS, compared with usual care, include
an additional 3900 people becoming physically active,
51 cases of CHD avoided, 16 cases of stroke avoided, 86
cases of diabetes avoided, 152 additional people in health
states devoid of CHD, stroke or diabetes and a gain of
800 QALYs [a product of QALYs gained over the lifetime
of an individual exposed to ERS (i.e. 0.008) and the
number of individuals (100 000)]. ERS is also expected to
positively affect the prevention or/and management of
mental health, metabolic disease, cancer and musculo-
skeletal conditions as well as productivity through reduced
absenteeism at work. There are potential adverse affects in
terms of injuries and pain which are considered rare10,16
but could still negate some of the positive impacts of
ERS. Based on the quantiﬁable costs and beneﬁts, ERS
is expected to result in a positive net beneﬁt of 0.008
QALYs. This is expected to be further improved by the
unquantiﬁed beneﬁts.
Sedentary
ERS
No ERS
Not active
Active
None
Diabetes
Stroke
CHD
Active
Not active
Fig. 1 Diagram of the decision analytic model used in the CUA. The model
adopts a lifetime horizon and NHS/Personal Social Services perspective.
A cohort of sedentary individuals exposed to an ERS is considered. Label
nodes ( ) signify that the branches indicating the outcomes (i.e. CHD,
stroke, diabetes and none) apply.
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Discussion
Main findings
Our ﬁndings suggest that ERS is cost-effective when com-
pared with widely accepted thresholds for cost-effectiveness.
However, caution should be taken in focusing on the ICER
value alone. Our analysis suggests that ERS results in only a
marginal beneﬁt in terms of QALYs at a modest cost,
hence the favourable ICER. It should be noted though, that
the QALY gain is based on relatively poor quality evidence
on the effectiveness of ERS.
Whilst the CUA provides a useful composite outcome,
in the form of the ICER, stakeholders with an interest in
the planning and delivery of ERS are likely to be some-
what frustrated by this approach. One might ask how
meaningful a change of 0.008 in lifetime QALYs is to an
individual and how this evidence can be used to (i) make
the business case for investment in ERS and monitor
its impact over time and (ii) convince participants of its
beneﬁts.
The CCA goes some way to addressing this issue
by reporting the outcomes in natural units likely to resonate
with those involved in the planning and delivery of ERS
as well as participants. Identifying changes in the number
of occurrences and the related resources provides a
more meaningful measure of effectiveness for many stake-
holders, particularly those from the non-health sector, such
as local authorities and business. Furthermore, reporting the
outcomes in a disaggregated fashion, including those where
it might not be possible to quantify the scale of the effect,
allows stakeholders to identify costs and beneﬁts that they
are likely to accrue and plan appropriately and, more im-
portantly, put in place monitoring systems that can detect
whether the beneﬁts of ERS are being realized in practice.
This disaggregated approach to evaluation might also
provide information on how ERS can contribute to meeting
speciﬁc priorities or addressing inequalities within a popula-
tion (e.g. reduction in number of strokes or episodes of
cancer). On this basis, the CCA is expected to be an attract-
ive form of evaluation in public health settings and resonate
with a broader range of stakeholders.
What is already known about this topic?
Many commentators have recognized the limitations of
methods of economic evaluation when applied to public
health as these methods are based on a pharmaceutical
paradigm2,3 However, to date, there is paucity of studies ex-
ploring the issue of the appropriate method to apply to eco-
nomic evaluations of public health interventions.
Table 2 Cost-effectiveness results (after deterministic sensitivity analyses) comparing ERS with usual care
Parameters/scenarios How data were adjusted for in the model Incremental cost
per person
Incremental effect
per person (QALY)
ICER
Base case analysis — £170 0.008 £20 876
Parameters
Intervention costs to
participants
Costs of intervention was varied from £222 to £342
(including costs to providers and participants)
£290 0.008 £35 652
Less intensive ERS Costs of intervention was varied from £222 to £110 £58 0.008 £7085
Effectiveness of ERS (based on
lower limit of 95% CI)
Probability of becoming active after exposure
to ERS was varied from 0.336 to 0.294
£226 20.001 Dominateda
Effectiveness of ERS (based
upper limit of 95% CI)
Probability of becoming active after exposure
to ERS was varied from 0.336 to 0.371
£122 0.015 £7947
Scenarios
Worst-cases of cost and
effectiveness
Worst-case cost (£342) and worst-case
effectiveness (0.294)
£346 20.001 Dominateda
Best cases of cost and
effectiveness
Best-case cost (£110) and best-case
effectiveness (0.371)
£10 0.015 £679
Worst-case cost and best-case
effectiveness
Best-case cost (£110) and worst-case
effectiveness (0.294)
£242 0.015 £15 734
Best-case cost and worst-case
effectiveness
Worst-case cost (£342) and best-case
effectiveness (0.371)
£114 20.001 Dominateda
aERS more costly and less effective than usual care.
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What this study adds?
Our work contributes to ﬁlling this gap in knowledge by
showing that CCA might be most suitable to public health
interventions, using ERS as an exemplar. This is not to
dismiss CUA. CCA and CUA are, essentially, two sides of
the same coin. Much of the information reported in the
CCA is captured in the composite outcomes of the CUA.
However, the granularity with which the ﬁndings of the
CCA are reported is expected to be desirable to stakeholders
involved in planning public health interventions. Investment
in public health might seem as a high risk by some stake-
holders, given the level of uncertainty around the
Table 3 Results of cost-consequence analysis (using a cohort of 100,000 individuals)
Measures in analysis Potential impact of ERSs on measures
Costs
Intervention cost to providers £22 200 000 (2010 prices)
Intervention cost to participants £12 000 000 (2010 prices)
Benefits
Physically active state 3900 additional physically active people
Non-disease health state 152 extra people in non-disease health state
Mental health
Anxiety Reduced anxiety in participants with the magnitude of the effect size being 0.219
Depression Increased the success rate to 67–74% reduction in depressive symptoms
Metabolic
Diabetes Avoided 86 extra cases of type II diabetes
Led to small but significant reduction in glycosylated haemoglobin (0.7%). This amount is likely to
reduce diabetes complications
Cancer
Colon cancer A 30–40% reduction in the risk of developing colon cancer
Breast cancer A 20–30% reduction in the risk of developing breast cancer
Lung cancer A 20% reduction in the risk of developing lung cancer
Cardiovascular
Hypertension Decreased systolic blood pressure by 3.8 mm Hg and diastolic blood pressure by 2.6 mm Hg in samples of both
hypertensives and normatensives
In hypertensives, systolic blood pressure was reduced by 4.94 mm Hg and diastolic blood pressure
by 3.73 mm Hg
In normatensives, systolic blood pressure was reduced by 4.04 mm Hg and diastolic blood pressure
by 2.33 mm Hg
CHD Avoided 51 extra cases of CHD
Reduced all-cause mortality [odds ratio (OR): 0.80; 95% CI: 0.68–0.93] and cardiac mortality
(OR: 0.74; 95% CI: 0.61–0.96)
Stroke Avoided 16 extra cases of stroke
Musculoskeletal
Osteoporosis A hip fracture risk reduction of 45% (95% CI: 31–56%) and 38% (95% CI: 31–44%), respectively, among men
and women
Osteoarthritis Pooled effect sizes for pain were between 0.39 and 0.52
For self-reported disability, pooled effect sizes ranged from 0.32 and 0.46
Low back pain Pooled mean improvement (measured on a scale of 100 points) was 7.3 points (95% CI: 3.7–10.9 points) for
pain and 2.5 points (CI: 1.0–3.9 points) for function
Rheumatoid arthritis Improved function by 0.24 (measured via the HAQ score) and pain by 0.31 (measured via the HAQ score)
Falls prevention Beneficial effect on the risk of falls (adjusted risk ratio: 0.86, 0.75–0.99)
Absenteeism at work Lower absenteeism at work (effect size ¼ 0.19)
Adverse effects
Injury Increased the risk of musculoskeletal injury by about four times
Disability Walking (more than three city blocks) increased the risk of walking disability because of severe pain (OR: 4.1–5.0)
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effectiveness of many of the interventions and the fact that
many of the health beneﬁts are unlikely to occur for a gen-
eration.17 This perception might be exacerbated by CUA
which report composite outcomes modelled over the life-
time of an individual, often based on fairly heroic assump-
tions about behaviour change. By breaking down the
outcomes into more discrete units, decision-makers are
better able to understand the potential costs and beneﬁts. A
further improvement to our own analysis would be to in-
corporate time into the outcomes, so that decision-makers
can identify when costs and beneﬁts are likely to be
accrued. That would allow decision-makers to monitor
short-term or proxy outcomes to ensure that interventions
are delivering on their promise of long-term improvements
in health outcomes.
Health economists involved in the assessment of public
health interventions are encouraged to engage with health
service, and increasingly, local authority commissioners to
better understand their needs. CUA remains a powerful
tool, providing a common currency with which the cost-
effectiveness of healthcare interventions can be compared.
However, this common currency has little resonance with
stakeholders from the non-health sector. Given the multi-
sectoral nature of public health, it is important that costs
and beneﬁts are presented transparently if the case is to be
made for continued investment
Limitations
The analysis had a number of limitations. First, the CUA
examined only the long-term impact of physical activity on
selected morbidities. It was not possible to include other
morbidities which may be affected by physical activity due
to uncertainty over the relationship between physical activity,
incidence and quality-adjusted life-expectancy. Secondly, the
assumption that the average age of onset of a disease health
states is 55 years might not be realistic as it could vary by
demographics and disease conditions.6 Thirdly, interventions
which involve complex behaviour change may not be well
suited to decision analytic models. Individual level simula-
tion models which can detect changes in individual beha-
viours over time may better address cost-effectiveness.
However, there will be a trade-off between developing a
simple model, which can be populated and acknowledges its
limitations versus a more complex model which may be a
better representation of reality but can only be partially
populated and may result in greater uncertainty. In all cases,
the fundamental issue which needs to be addressed is im-
provement in the source data.
Conclusion
There is an increasing demand to consider the cost-
effectiveness of investments in public health programmes.
Prevailing methods of economic evaluation, such as CUA,
which have been developed largely for the assessment of
medical technologies may have limited applicability to public
health interventions. CCA provides greater transparency when
considering costs and consequences that might be accrued by
a wide range of stakeholders in the public and private sectors
and might also usefully provide a means of monitoring the
short-term progress of public health programmes.
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